NasdaqGM - Nasdaq Real Time Price USD

Iovance Biotherapeutics, Inc. (IOVA)

Compare

7.83

-0.13

(-1.63%)

At close: December 13 at 4:00:02 PM EST

8.03

+0.20

(+2.56%)

After hours: 7:59:19 PM EST

Prediction: This Stock Will Beat the Market in 2025

It hasn't been a great year for Iovance Biotherapeutics (NASDAQ: IOVA), an innovative mid-cap biotech company. Let's look deeper into how Iovance Biotherapeutics could pull that off. It is manufactured using patients' own TIL cells, which can identify and kill cancer cells.

Motley Fool yesterday

IOVA
-1.63%
3 Monster Stocks to Hold for the Next 10 Years

Just be ready to ride out some inevitable turbulence along the way.

Motley Fool 6 days ago

PANW

WOLF

IOVA
-1.63%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%

Key Insights Institutions' substantial holdings in Iovance Biotherapeutics implies that they have significant influence...

Simply Wall St. 10 days ago

IOVA
-1.63%
Is Iovance Biotherapeutics Stock a Millionaire Maker?

The biotech industry has been described as the Wild West of the stock market. While that level of success is only obvious in hindsight, Iovance Biotherapeutics (NASDAQ: IOVA) is an emerging industry leader with significant potential. This has been a milestone year for Iovance Biotherapeutics.

Motley Fool 16 days ago

IOVA
-1.63%
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Raj Puri, M.D., Ph.D. has been promoted to the newly created role of Chief Regulatory Officer. Dr. Puri joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medic

GlobeNewswire 17 days ago

IOVA
-1.63%
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back

As the rising star of cell therapy biotechs, Iovance Biotherapeutics (NASDAQ: IOVA) is a hot stock that's capturing a lot of attention, and for good reason. Today, Iovance has a trio of bullish drivers are the legs of the stock's investment thesis. First, Iovance's first cell therapy to be approved for sale, Amtagvi, is quickly finding its home in the market.

Motley Fool 20 days ago

IOVA
-1.63%
Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against the other promising cancer stocks. According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, […]

Insider Monkey 20 days ago

IOVA
-1.63%
2 Innovative Stocks That Could Deliver Outsize Returns

It's too late to get in on the ground floor with those that are already well-established leaders in their fields, but there are plenty of smaller, highly innovative companies that could deliver excellent returns as they gain in prominence. In that spirit, let's discuss two in the healthcare sector that could make breakthroughs and deliver market-beating returns along the way: Iovance Biotherapeutics (NASDAQ: IOVA) and Recursion Pharmaceuticals (NASDAQ: RXRX). Iovance Biotherapeutics is a cancer-focused biotech.

Motley Fool 21 days ago

IOVA
-1.63%
RXRX
Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he […]

Insider Monkey 21 days ago

IOVA
-1.63%
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Iovance Biotherapeutics ( NASDAQ:IOVA ) Third Quarter 2024 Results Key Financial Results Revenue: US$58.6m (up by...

Simply Wall St. last month

IOVA
-1.63%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its quarterly report and things are looking bullish...

Simply Wall St. last month

IOVA
-1.63%
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line

Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.

Zacks last month

IOVA
-1.63%
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...

Iovance Biotherapeutics Inc (IOVA) reports strong Q3 2024 revenue, exceeding guidance, while addressing challenges and setting ambitious targets for 2025.

GuruFocus.com last month

IOVA
-1.63%
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 9.68% and 9.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

IOVA
-1.63%
Iovance Biotherapeutics: Q3 Earnings Snapshot

SAN CARLOS, Calif. AP) — Iovance Biotherapeutics Inc. IOVA) on Thursday reported a loss of $83.5 million in its third quarter.

Associated Press Finance last month

IOVA
-1.63%
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2

GlobeNewswire last month

IOVA
-1.63%
High Growth Tech Stocks to Watch in November 2024

Over the last 7 days, the United States market has dropped 1.9%, yet it remains up by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these promising earnings projections.

Simply Wall St. last month

APLS
+1.37%
IOVA
-1.63%
EXAS
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

Iovance also to Participate in Upcoming November ConferencesSAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024. Q3 2024 Financial Results Conference CallManagement will host a conference c

GlobeNewswire last month

IOVA
-1.63%
Why Iovance Biotherapeutics Stock Triumphed on Thursday

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.

Motley Fool last month

IOVA
-1.63%
State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc

Overview of the Recent Transaction State Street Corp, a prominent investment firm, recently expanded its portfolio by acquiring 13,201,978 shares in Iovance Biotherapeutics Inc (NASDAQ:IOVA). This transaction, which took place on September 30, 2024, signifies a notable addition strategy by the firm, reflecting a bullish stance on the biotechnology sector. The shares were purchased at a price of $9.39, marking a significant investment in the clinical-stage biopharmaceutical company.

GuruFocus.com last month

IOVA
-1.63%
STT

Performance Overview

Return	IOVA	S&P 500
YTD	-3.69%	+26.86%
1-Year	+22.54%	+30.31%
3-Year	-57.61%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Iovance Biotherapeutics, Inc. (IOVA)

Prediction: This Stock Will Beat the Market in 2025

3 Monster Stocks to Hold for the Next 10 Years

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%

Is Iovance Biotherapeutics Stock a Millionaire Maker?

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back

Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds

2 Innovative Stocks That Could Deliver Outsize Returns

Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line

Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...

Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates

Iovance Biotherapeutics: Q3 Earnings Snapshot

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

High Growth Tech Stocks to Watch in November 2024

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

Why Iovance Biotherapeutics Stock Triumphed on Thursday

State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc

Performance Overview